News
AdventHealth Adopts Paragonix SherpaPak™ Cardiac Transport System
Paragonix SherpaPak™ Cardiac Transport System is the only FDA cleared and CE marked device that safeguards hearts between donor and recipient patients CAMBRIDGE, Mass.–(BUSINESS WIRE)–Paragonix
FDA Clears Paragonix Technologies’ LUNGguard for Donor Lung Preservation
CAMBRIDGE, Mass.–(BUSINESS WIRE)– Paragonix Technologies Inc.today announced clearance of a Pre-Marketing Notification (510(k)) with the US Food and Drug Administration (FDA) for its Donor Lung Preservation
Paragonix Technologies, Inc., Announces First Successful Use of Paragonix SherpaPak™ Cardiac Transport System in Pediatric Transplant Recipients
Paragonix Technologies, Inc. today announced that the first series of pediatric donor hearts preserved and transported using Paragonix SherpaPak Cardiac Transport System occurred at University of Florida Health (UF Health) and Le Bonheur Children’s Hospital (TN). Starting in Q1 2019, Paragonix SherpaPak™ CTS have been shipped with heart connectors covering most aortic diameters, permitting the anchoring of variously sized hearts, including small pediatric hearts, to its proprietary suspension system for improved donor heart transport.
Paragonix Technologies, Inc. Announces FDA Clearance and U.S. Launch of the Paragonix SherpaPak™ Pancreas Transport System
Paragonix Technologies, Inc. today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Paragonix SherpaPak™ Pancreas Transport System (PTS). Starting immediately, the Paragonix SherpaPak™ PTS will be commercially available to pancreas transplant centers and Organ Procurement Organizations. The Paragonix SherpaPak PTS provides unprecedented thermal and physical protection to the donor pancreas during transport from donor to recipient patients.
Surgeons at Duke University Hospital Use Advanced Preservation and Transportation System to Safeguard Donor Heart During Journey Between Donor and Recipient
DURHAM, N.C.–(BUSINESS WIRE)-Duke University Hospital has transported its first donor heart using the only commercially available FDA cleared and CE marked system for cold donor
Paragonix Technologies Cares Program
Paragonix Technologies is happy to announce that we will be sponsoring pet therapy at the University of Florida! Pet therapy can go a long way
Paragonix SherpaPak™ Cardiac Transport System Fellowship Program
Paragonix Technologies is excited to announce that we will be sponsoring a program to train fellows in the use of the Paragonix SherpaPak™ Cardiac Transport System.
Paragonix Technologies Sponsors Lung Transplant Hiking Expedition
Paragonix Technologies is immensely proud to sponsor one of the most amazing sporting events of 2019: an expedition of a group of 50 patients and
The Favaloro Foundation First in South America to Preserve & Transport Donor Heart with Paragonix
CAMBRIDGE, Massachusetts & Buenos Aires, Argentina—Paragonix Technologies, Inc. today announced that the Paragonix SherpaPak™ Cardiac Transport System (CTS), the industry’s only FDA cleared and CE marked
Paragonix SherpaPak™ Cardiac Transport System to be Featured in Clinical Presentation at 2019 American Transplant Congress
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Paragonix Technologies, Inc. today announced that the Paragonix SherpaPak™ Cardiac Transport System (CTS), the industry’s only FDA cleared and CE marked system for donor organ heart transport and storage, will be featured in a clinical presentation at the 2019 American Transplant Congress. The meeting is being held June 1-5, 2019 in Boston.
Paragonix Announces Transplanted-Cost Savings & Clinical Results for Donor Heart Preservation using SherpaPak Cardiac Transport System in Routine & Complex Heart Transplantation
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Paragonix Technologies, Inc. today announced clinical results presented during the Paragonix SherpaPak™ CTS 2019 International Heart Summit held during the International Society for Heart and Lung Transplantation (ISHLT) 2019 Annual Meeting in Orlando, FL. Five U.S. and European Centers shared clinical use experiences of the Paragonix SherpaPak™ Cardiac Transport System (CTS) for the preservation of donor hearts destined for heart transplantation.
Paragonix & the Lung Transplant Foundation Announce Expansion of Partnership to Accelerate Commercialization of Innovative Lung Preservation Technologies
CAMBRIDGE, Mass.–(BUSINESS WIRE)– Paragonix Technologies Inc., and the Lung Transplant Foundation (LTF) today announced an expansion of their partnership for the development of a series of innovative technologies for
Paragonix Initiates Global Post Market Registry Evaluating Clinical Outcomes in Patients who Receive Donor Hearts Transported with Paragonix SherpaPak™ Cardiac Transport System
CAMBRIDGE, Mass.–(BUSINESS WIRE)– Paragonix Technologies, Inc. today announced the opening of the Global Utilization And Registry Database for Improved heArt preservatioN (“GUARDIAN”) post-market registry, which will assess
Paragonix SherpaPak Cardiac Transport System to be Demonstrated at the International Society for Heart and Lung Transplantation 2019 Annual Meeting
CAMBRIDGE, Mass.–(BUSINESS WIRE)– Paragonix Technologies, Inc. today announced that it will be exhibiting at the International Society for Heart and Lung Transportation (ISHLT) 2019 Annual Meeting, from April 3rd to 5th at the Loews Meeting Complex in Orlando, Florida.
